Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?

Uyar, Enes; Ulaş, Fatih; Alkan, Yunus

doi:10.1080/02713683.2020.1789664

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The amount of VR was evaluated by measuring the diameter of the broadest conjunctival formation with a ruler. Patients were allocated to one of the three groups according to their VR status: group 1, patients had no VR; group 2, patients had a conjunctival bleb diameter of <3 mm; and group 3, patients had a conjunctival bleb diameter of >3 mm [9,14] . The axial length, anterior chamber depth and lens thickness of all patients were measured using an IOLMaster 700 (Carl Zeiss Meditec AG, Jena, Germany).…”

Section: Subjects and Methods Ethical Approvalmentioning

confidence: 99%

Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes

Muto,

Imaizumi

2024

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To evaluate the effect of background diseases and number of previous intravitreal aflibercept injections (IVAIs) on immediate intraocular pressure (IOP) increase and vitreous reflux (VR) rate and to evaluate the correlation of both age and axial length with immediate IOP increase and VR rate. METHODS: This study included 105 patients with cystoid macular edema secondary to retinal vein occlusion, 35 patients with diabetic macular edema, 69 patients with neovascular age-related macular degeneration (nAMD), and 12 patients with myopic choroidal neovascularization, which underwent first-time IVAI. The correlation of immediate IOP increase and VR rates with the four background diseases was investigated. Moreover, the correlation of age with immediate IOP increase and VR rate as well as correlation of axial length with immediate IOP increase and VR rate were evaluated. Further, 54 patients with nAMD were treated with IVAI>10 times (multiple IVAIs). Moreover, the correlation of immediate IOP increase and VR rates with first-time and multiple IVAIs in nAMD was determined. RESULTS: The immediate IOP increase (P=0.16) and VR rates (P=0.50) were almost similar among the four background diseases. The immediate postinjection IOP and age, VR rate and age, immediate postinjection IOP and axial length, or VR rate and axial length were not correlated in the four background diseases. The immediate IOP increase (P=0.66) and VR rates (P=0.28) did not significantly differ between first-time and multiple IVAIs in nAMD. CONCLUSION: Background diseases and number of previous IVAIs have no effect on immediate IOP increase and VR rate. Further, age and axial length have no correlation on immediate IOP increase and VR rate.

show abstract

Section: Subjects and Methods Ethical Approvalmentioning

confidence: 99%

Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes

Muto,

Imaizumi

2024

Int J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Refluxes from injection site do not affect the therapeutic effect of the drug injected intravitreally. Uyar et al evaluated the effect of reflux from the injection site on the therapeutics of intravitreal ranibizumab, and concluded that reflux from the injection site did not affect the decrease in macular thickness in diabetic and Agerelated macular degeneration (AMD) patients (24) . Similar results were reported by Tanwar et al, showing that reflux did not cause a therapeutic compromise in terms of best-corrected visual acuity (BVCA) and macular thickness following intravitreal injection (25) .…”

Section: P R O V I S I O N a L L Ymentioning

confidence: 99%

Intra-ocular pressure changes after intravitreal injection of bevacizumab

Iqbal

Malik²,

Jabran³

2022

J Pak Med Assoc

View full text Add to dashboard Cite

Objectives: To evaluate the short-term and sustained intraocular pressure changes after intravitreal bevacizumab in patients with diabetic retinopathy. Method: The quasi-experimental study was conducted at the District Headquarter Teaching Hospital, Gujranwala, Pakistan, from January to December 2020, and comprised diabetic patients of either gender aged 18-60 years with indication for intravitreal bevacizumab. Intraocular pressure was measured at 5, 10 and 30 minutes for short-term elevation, and the patients were followed up weekly for one month to record any sustained elevation in intraocular pressure. Data was analysed using SPSS 25. Results: Of the 42 patients, 20(47.61%) were male and 22(52.38%) were female. The overall mean age was 52.4±5.7 years. Intraocular pressure increased significantly in the short term post-injection (p<0.001), while the difference was not significant in the weekly check-ups (p=0.264). Conclusion: There was short-term rise in intraocular pressure after intravitreal bevacizumab, but no sustained elevation was noted over the following month. Key Words: Vascular endothelial growth factor, Bevacizumab, Intraocular pressure, Diabetic retinopathy.

show abstract

Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real‐World Study

Muto,

Sakamoto,

Machida

et al. 2024

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. This study aimed to evaluate the therapeutic effect of vitreous reflux (VR) after intravitreal aflibercept injection (IVAI) for macular edema (ME) following naïve branch retinal vein occlusion (BRVO). Methods. Eighty patients with ME following BRVO were divided into three groups according to the conjunctival bleb diameter after IVAI as follows: group A (no VR), group; B (<3 mm VR), and group C (>3 mm VR). Each patient received single IVAI. The treatment response was evaluated with the best‐corrected visual acuity (BCVA) and optical coherence tomography measurements of the retinal foveal thickness (RFT) before treatment and 1 month after the first injection. RFT >375 μm was defined as recurrence and received additional IVAI. The recurrence rate of ME and total numbers of IVAI were investigated at 12 months. Results. The BCVA values at 1 month were 0.17 ± 0.29 in group A (n = 41), 0.18 ± 0.17 in group B (n = 18), and 0.19 ± 0.26 in group C (n = 21). The RFT at 1 month were 270 ± 45 μm in group A, 279 ± 24 μm in group B, and 290 ± 43 μm in group C, respectively. ME recurred in 29 out of 41 patients in group A, 15 out of 18 in group B, and 14 out of 21 in group C. The total numbers of IVAI were 2.50 ± 1.24 in group A, 2.59 ± 1.06 in group B, and 2.29 ± 1.27 in group C, respectively. In the abovementioned comparisons, no significant differences were found following an IVAI (P > 0.05). Conclusions. VR after IVAI did not affect the therapeutic effect in patients with ME following BRVO. Thus, we do not need to pay excess attention to VR in the case of IVAI.

show abstract

Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?

Cited by 3 publications

References 29 publications

Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes

Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes

Intra-ocular pressure changes after intravitreal injection of bevacizumab

Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real‐World Study

Contact Info

Product

Resources

About